Can Psilocybin Ease the Fear of Dying?

Medicine has become increasingly capable of extending life.

It remains less capable of answering one of the oldest human problems: what happens psychologically when we are forced to confront the possibility of our own death?

For people living with cancer and other life-threatening illnesses, suffering does not always come from physical symptoms alone. Anxiety, depression, hopelessness, demoralization and fear of death can profoundly affect quality of life.

Psychotherapy, medication, spiritual care and palliative support can help. But some forms of existential distress remain difficult to treat.

Over the past decade, researchers have revisited an unusual possibility: could psilocybin change not the reality of mortality, but a person's relationship with it?

Early clinical trials suggest it might.

The evidence is intriguing. It is also considerably more limited than the enthusiasm surrounding psychedelic medicine sometimes implies.

The Psychological Weight of Mortality

Fear of death is not necessarily a psychiatric disorder.

It is also not inherently irrational.

For someone confronting a life-threatening diagnosis, anxiety may arise from uncertainty, anticipated suffering, separation from family, loss of independence, changes in identity or simply the knowledge that life may be shorter than expected.

That distinction matters.

Treating distress surrounding serious illness is not necessarily about convincing someone that there is nothing to fear.

The deeper therapeutic question may be whether a person can relate differently to circumstances that medicine itself cannot change.

This is one reason psilocybin research in cancer has attracted unusual interest.

Unlike a conventional anxiolytic intended primarily to reduce symptoms, psilocybin can produce profound changes in perception, emotion, sense of self and personal meaning.

Researchers have therefore been investigating not only whether symptoms improve, but what happens during the experience that might help explain why.

Why Psilocybin?

Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms.

After ingestion, the body converts psilocybin into psilocin, which produces its characteristic psychoactive effects largely through serotonin 5-HT2A receptor activity.

But describing receptor activity does not fully describe the experience.

Under psilocybin, people may experience significant changes in perception, emotion, time, self-awareness and their sense of connection to other people or the world around them.

Some experiences are described as deeply meaningful or mystical.

Others can be difficult or frightening.

Clinical research therefore typically does not investigate psilocybin simply as a pill taken in isolation. Studies commonly involve participant screening, preparation, supervised dosing sessions and psychological support.

That makes an important question surprisingly difficult to answer:

If people improve, what exactly produced the improvement?

The drug?

The psychological support?

Expectation?

The experience itself?

Or some interaction among all of them?

What the Landmark Cancer Studies Found

Two influential randomized trials published in 2016 helped renew scientific interest in this question.

At New York University, researchers studied 29 people with cancer-related anxiety and depression.

Participants received a single moderate dose of psilocybin or an active placebo, niacin, in conjunction with psychotherapy before later crossing over to the other condition.

Before crossover, the psilocybin condition was associated with substantial reductions in anxiety and depression as well as reductions in cancer-related demoralization and hopelessness, improvements in spiritual wellbeing and quality of life, and changes in attitudes toward death.

At the 6.5-month follow-up, approximately 60–80% of participants continued to show clinically significant reductions in depression or anxiety.

At Johns Hopkins, a separate randomized study included 51 people with life-threatening cancer and symptoms of depression and/or anxiety.

Researchers compared a very low, placebo-like psilocybin dose with a substantially higher dose.

The higher-dose condition was associated with substantial reductions in depressed mood and anxiety and increases in quality of life, meaning and optimism. Death anxiety also decreased.

At six months, roughly 80% of participants continued to demonstrate clinically significant decreases in depressed mood or anxiety.

For studies involving relatively small numbers of participants, those were striking results.

They were not definitive ones.

What Has Research Found Since?

Subsequent research has continued to produce encouraging signals.

A 2025 report followed participants from a Phase 2 study involving people with cancer and major depressive disorder who had received a single 25 mg dose of psilocybin combined with psychological support.

Among 28 people included in the two-year follow-up, 15 showed significant reductions in depression and 14 had sustained depression reduction. Thirteen showed significant anxiety reduction, with 12 maintaining that improvement at follow-up.

These results are noteworthy because they raise the possibility that benefits may persist well beyond the acute psychedelic experience.

But follow-up studies have important limitations.

Participants are not living in experimental isolation for two years. Their health can change. They may receive other treatments. Relationships and circumstances evolve. And once everyone has received the active intervention, long-term improvement cannot automatically be attributed solely to psilocybin.

More recent analyses have nevertheless continued to find an encouraging overall signal.

A 2026 systematic review and meta-analysis examining psilocybin and psychological distress among people with cancer found significant reductions in depressive symptoms across randomized trials. The authors also examined anxiety and other psychological outcomes.

The direction of the evidence is increasingly difficult to dismiss.

Its limits remain equally important.

The total evidence base is still relatively small compared with established psychiatric treatments, and studies vary in design, dose, psychological support and patient population.

What Happens to the Fear of Death?

This may be the most interesting part of the research.

The early cancer studies did not report changes only in conventional depression and anxiety scores.

Researchers also observed changes in:

death anxiety

demoralization

hopelessness

meaning

optimism

spiritual wellbeing

and attitudes toward death.

That raises a different possibility.

Perhaps some participants were not simply becoming less anxious.

Perhaps something about the way they understood themselves, their illness or mortality had changed.

That distinction is difficult to capture on a symptom scale.

It also takes us into territory where medicine, psychology and subjective experience begin to overlap.

Does the Mystical Experience Matter?

In the NYU trial, researchers reported that the intensity of the psilocybin-associated mystical experience statistically mediated therapeutic effects on anxiety and depression.

That finding is provocative.

It does not establish that mystical experiences themselves are medical treatments.

Nor does it prove that a person needs a mystical experience in order to benefit from psilocybin.

A statistical relationship can have several explanations.

People who respond more strongly to the drug may both experience greater subjective effects and greater therapeutic effects. Expectations may matter. Psychological support may influence how an experience is interpreted. Other biological or psychological mechanisms could contribute to both.

The broader scientific question therefore remains unresolved:

Is the extraordinary subjective experience an essential part of psychedelic therapy—or an accompanying effect of a drug whose therapeutic mechanisms ultimately lie elsewhere?

Researchers are still trying to answer it.

For people confronting mortality, however, the question has another dimension.

If someone's suffering involves meaning, identity and fear of nonexistence, perhaps a profound change in perspective is not merely a side effect.

Perhaps perspective is part of what is being treated.

That remains a hypothesis—not an established medical fact.

But it is one of the reasons this area of research is so unusual.

A Curious Parallel: Near-Death Experiences

Another line of research has compared psychedelic experiences with spontaneous near-death and other extraordinary experiences.

People in both groups have sometimes reported lasting changes in their attitudes toward death and dying.

This does not demonstrate that psychedelic experiences and near-death experiences are neurologically identical, nor does it establish anything about what happens after death.

It does suggest that certain profound alterations in conscious experience may influence how people subsequently think about mortality.

For Brazen, that distinction is important.

A person's interpretation of an experience may be psychologically consequential even when science cannot validate the metaphysical interpretation attached to it.

The experience is real.

What the experience ultimately means is a different question.

What Do We Know About Safety?

The word safe requires context.

Controlled psilocybin studies have generally reported that administration can be conducted with an acceptable safety profile in carefully screened participants under supervised research conditions.

That does not establish that psilocybin is safe for everyone.

Clinical studies typically screen participants for medical and psychiatric factors that could increase risk. Dosing takes place in controlled environments with trained personnel and psychological preparation and support.

Psilocybin can acutely alter perception, cognition, emotion, heart rate and blood pressure. Difficult psychological experiences can occur.

This distinction becomes particularly important in people with serious illness, who may have complex medical conditions or take multiple medications.

The appropriate conclusion from clinical research is therefore not:

“Psilocybin is safe for end-of-life anxiety.”

It is:

Psilocybin has been administered in carefully controlled clinical studies involving selected patients with serious illness, with encouraging safety and tolerability findings that justify continued research.

Those are very different claims.

Why Isn't This Standard Palliative Care?

Despite promising findings, psilocybin is not an FDA-approved treatment for cancer-related anxiety, depression, existential distress or end-of-life anxiety.

It remains investigational for these uses in the United States.

In July 2026, FDA finalized guidance specifically addressing clinical investigations of psychedelic drugs, reflecting the agency's increasing engagement with the field while also highlighting the unusual challenges involved in developing these treatments.

FDA says it is supporting psychedelic-drug development, including investigation of potential treatments for serious mental-health conditions.

Regulatory engagement, however, is not regulatory approval.

Before psilocybin could become an established medical treatment for distress associated with serious illness, researchers and regulators would need greater clarity around questions including:

Who should receive it?

Who should not?

What dose and treatment model should be used?

How much psychological support is necessary?

Which professionals should provide that support?

How durable are the benefits?

What are the uncommon but serious risks?

And can outcomes observed in specialized research environments be reproduced in ordinary healthcare settings?

These are implementation questions as much as scientific ones.

A Different Kind of Therapeutic Goal

There is another reason this research deserves attention.

Much of medicine is organized around changing an undesirable physical reality.

Remove the tumor.

Kill the infection.

Lower the blood pressure.

Reduce the inflammation.

But mortality presents medicine with a boundary it ultimately cannot cross.

For someone living with an incurable illness, successful psychological treatment cannot necessarily remove the underlying source of fear.

The illness may still exist.

Death may still be approaching.

So what constitutes a therapeutic effect?

Less anxiety?

Greater acceptance?

More meaning?

An improved ability to spend the remaining time engaged with family and life?

A reduced fear of dying?

Those outcomes can be measured imperfectly, but they also raise philosophical questions about what medicine is attempting to accomplish when it cannot change the final outcome.

Psilocybin research sits unusually close to that boundary.

What We Know

Small randomized clinical trials have found substantial reductions in depression and anxiety following psilocybin administered with psychological support among selected people facing cancer and other life-threatening illness.

Some studies have also reported improvements in death anxiety, demoralization, hopelessness, meaning, spiritual wellbeing and quality of life.

Longer-term follow-up has found that improvements persisted among some participants months or years later, although those study designs cannot establish that psilocybin alone caused the long-term outcomes.

A 2026 systematic review and meta-analysis found an overall signal supporting further investigation of psilocybin for psychological distress among people with cancer.

What We Don't Know

We do not yet know how well these findings will generalize to larger and more medically diverse populations.

We do not know the optimal treatment model.

The relative contributions of psilocybin, psychological support, expectation, treatment environment and subjective experience remain difficult to separate.

Long-term efficacy requires more rigorous investigation.

The role of mystical-type experiences remains unresolved.

And carefully screened clinical-trial participants should not be assumed to represent every person facing terminal or life-threatening illness.

Most importantly, promising research should not be confused with an approved treatment.

The Question That Remains

Death anxiety presents medicine with an unusual problem.

Death itself cannot ultimately be treated.

But our relationship with mortality may not be fixed.

The early science surrounding psilocybin suggests that, for some people facing serious illness, a profound alteration in consciousness may be associated with equally profound changes in anxiety, meaning and attitudes toward death.

Whether those effects can be reliably reproduced, safely delivered and scientifically understood remains an open question.

But perhaps the most interesting question is even more fundamental:

If a medicine cannot change the fact of death, but can change a person's relationship with it, what exactly are we treating?

Sources & Further Reading

This article draws primarily on peer-reviewed randomized clinical trials, longer-term follow-up research, systematic reviews and current U.S. Food and Drug Administration guidance.

Because psychedelic medicine is a rapidly developing field, readers should consider the Last Reviewed date when interpreting research and regulatory information.

Editorial Note

The evidence discussed here comes largely from carefully controlled research involving selected participants, supervised administration and psychological support. Findings should not be generalized to unsupervised psychedelic use.

Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis or treatment. Psilocybin is not FDA-approved for cancer-related psychological distress or end-of-life anxiety. Decisions regarding mental-health or palliative care should be discussed with appropriately qualified healthcare professionals.